Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22347230 | 0.91 | NR1H4 (0.45) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347352 | 0.78 | NR1H4 (0.43) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347703 | 0.78 | NR1H4 (0.41) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22350451 | 0.76 | NR1H4 (0.45) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347558 | 0.72 | NR1H4 (0.46) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347813 | 0.72 | NR1H4 (0.37) | NR1H4CYP2C19 | |
| SCHEMBL22347355 | 0.72 | NR1H4 (0.46) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22348447 | 0.71 | HSD11B1 (0.51) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22352913 | 0.71 | NR1H4 (0.41) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347606 | 0.71 | HSD11B1 (0.44) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677659-B | Substituted amide compounds useful as farnesoid X receptor modulators | 百时美施贵宝公司 | 2024-09-06 | — | — | CN | disclosed |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3924329-A2 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020168152-A2 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168152-A2 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | NR1H4 2/4885NR1I2 8/4885CYP2C9 885/4885 |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | NR1H4 2/4885NR1I2 8/4885CYP2C9 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.